Evidence map›Paper›PMID 28365039›Full record

ArticleJournal of the American Academy of Dermatology2017

Tumor recurrence of keratinocyte carcinomas judged appropriate for Mohs micrographic surgery using Appropriate Use Criteria.

Sarah E Stuart, Patrick Schoen, Chengshi Jin, Rupa Parvataneni, Sarah Arron, Eleni Linos, W John Boscardin, Mary-Margaret Chren

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Academy of Dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Sarah E StuartDepartment of Dermatology (Program for Clinical Research), University of California, San Francisco, CA; College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA.
Patrick SchoenDepartment of Dermatology (Program for Clinical Research), University of California, San Francisco, CA; Population Services International, Washington, DC.
Chengshi JinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA.
Rupa ParvataneniDepartment of Dermatology (Program for Clinical Research), University of California, San Francisco, CA; Cardiovascular Research Foundation, New York, New York.
Sarah ArronDepartment of Dermatology (Program for Clinical Research), University of California, San Francisco, CA; San Francisco Veterans Affairs Medical Center, San Francisco, CA.
Eleni LinosDepartment of Dermatology (Program for Clinical Research), University of California, San Francisco, CA.
W John BoscardinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA; Department of Medicine, University of California, San Francisco, CA.
Mary-Margaret ChrenDepartment of Dermatology (Program for Clinical Research), University of California, San Francisco, CA; San Francisco Veterans Affairs Medical Center, San Francisco, CA. Electronic address: chrenm@derm.ucsf.edu.
University of California, San Francisco · USCardiovascular Research Foundation · USPopulation Services International · USSan Francisco VA Medical Center · USWestern University of Health Sciences · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
VARC CoreP30AG044281 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Louise C. Walter · 2013 to 2026
$19.9M
CTSA: K12 COMPONENTKL2RR024130 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$19.3M
Patient-Oriented Research in Skin DiseasesK24AR052667 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHREN, MARY-MARGARET · 2005 to 2014
$1.8M
Long-Term Outcomes of Nonmelanoma Skin CancerR01AR054983 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHREN, MARY-MARGARET · 2006 to 2009
$1.5M
NCATS NIH HHS UL1 TR000004NCRR NIH HHS KL2 RR024130NIAMS NIH HHS K24 AR052667NIAMS NIH HHS R01 AR054983NIA NIH HHS P30 AG044281
6 · The paper itself

Abstract

backgroundThe use of Mohs micrographic surgery (MMS) has increased greatly to treat basal cell and cutaneous squamous cell carcinomas (keratinocyte carcinoma [KC]), and consensus-based Appropriate Use Criteria (AUC) were developed to identify tumors for which MMS is appropriate.

objectiveWe sought to compare recurrence rates after different treatments in tumors judged appropriate for MMS.

methodsWe used data from an observational prospective cohort study and retrospectively categorized consecutive tumors as appropriate for MMS according to the AUC. Among appropriate tumors, we used survival analyses to compare 5-year recurrence rates after treatments.

resultsAmong tumors appropriate for MMS (N = 1483), adjusted 5-year recurrence rates were 2.9% (range, 1.4-4.3%) after MMS, 5.5% (range, 3.1-7.9%) after excision, 4.0% (range, 0.6-7.2%) after destruction, and 5.9% (range, 1.5-10.2%) after other treatments. In tumors treated only with MMS or excision (the most similar subgroups), the adjusted hazard ratio of 5-year recurrence after MMS was 0.6 (95% confidence interval, 0.3-1.0; P = .06). LIMITATIONS: This study is limited by its uncertain generalizability, lack of randomization, and unmeasured characteristics.

conclusionThe AUC identified tumors for which recurrence would be less common after MMS than after excision, but the absolute difference in recurrence rates was small.

Indexed as

Mohs SurgeryAgedBasal Cell CarcinomaCarcinoma, Squamous CellFemaleHumansMaleNeoplasm Recurrence, LocalProspective StudiesSkin NeoplasmsAppropriate Use Criteriabasal cell carcinomacutaneous squamous cell carcinomakeratinocyte carcinomaMohs micrographic surgeryoutcomes research

Identifiers

PMID28365039
PMCPMC5443650
OpenAlexW2602952246

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.